Acute Pericarditis With Declining Kidney Function: NSAID Escalation or Early Steroids?
Four days into standard NSAID and colchicine therapy, his pain hasn't resolved — and his declining kidney function is closing off the easy way to push the anti-inflammatory regimen harder.
R.M., a 58-year-old man, has run the overnight shift at a distribution warehouse for the past several months — a schedule change he took for the pay differential, one that has already made it harder to keep his blood pressure medications on a consistent clock. He came to the emergency department four days ago with sharp, positional chest pain that had built over the preceding week, on the tail of what he'd assumed was an ordinary head cold. Sitting forward eased it; lying flat did not. The ECG's diffuse ST elevation and PR depression, together with a three-component friction rub on exam, pointed away from an ischemic event and toward pericarditis — a reading his CRP of 62 and a mildly elevated troponin, more myocardial irritation than infarction, supported rather than contradicted.
He was started on ibuprofen 600 mg three times daily with colchicine 0.6 mg twice daily, the standard first-line combination, and sent home with instructions to return if the pain worsened. He is back on day four of therapy not because it worsened, but because it never meaningfully improved — still pleuritic, still positional, with a new low-grade fever overnight. What has changed since presentation is his kidney function: an eGFR of 52 at baseline, itself already reduced from long-standing hypertension, has fallen to 41 over four days of NSAID exposure. That decline sets a real ceiling on the most direct next move. Pushing the ibuprofen dose higher is the textbook answer to inadequate symptom control at day four, but it is also the most plausible driver of the renal trend already visible on his labs — and the same decline changes how his colchicine, cleared substantially by the kidney, is actually being handled at a dose chosen before any of this was known.
At the bedside, day four of therapy
Four days of unrelenting pericarditis pain in a patient who hasn't gotten meaningfully better on first-line therapy is exactly the group I'd normally push toward a higher NSAID dose or an early corticosteroid taper to get him comfortable. The complication here isn't the pericarditis — it's that his kidneys are telling us the drug he's already on is part of the problem, before we've even talked about adding a second one.
If his renal function were stable, I wouldn't be raising any of this. Escalating ibuprofen at day four for persistent pain is standard, unremarkable management — the argument is entirely about what his eGFR trend does to that standard step, not about whether it was ever reasonable.
I'd stop before we get to the steroid-versus-higher-NSAID question, because there's a problem sitting in his chart that neither option addresses: colchicine at 0.6 mg twice daily was never actually appropriate once his eGFR crossed below 50, and it's now sitting at 41. Colchicine is substantially renally cleared, and the toxicity margin is narrow — myelosuppression and severe GI effects, not a gentle overdose. Whatever we decide about ibuprofen or steroids, that dose needs correcting today, not as a footnote to the bigger debate.
The renal decline over four days is real and worth taking seriously, but a single eGFR drop this size with a normal urinalysis and no other injury markers is consistent with a reversible prostaglandin-mediated hemodynamic effect, not structural damage. That's a reason to be careful with the next NSAID decision, not a reason to conclude the kidney can't tolerate any further anti-inflammatory therapy at all.
Both of you are right about different pieces. The colchicine dose is the clearest, least controversial fix available today — halve it to 0.6 mg once daily, the standard adjustment in the 35 to 49 mL/min band — and worth noting that colchicine's renal dosing tables are indexed to CrCl rather than eGFR, so the estimate we act on should be the one those tables were built around — and that alone removes a real toxicity risk without touching the pericarditis question. On the NSAID-versus-steroid choice, the COPE trial data are worth being specific about: corticosteroid use during the initial episode is an independent, replicated risk factor for recurrence, not just a theoretical concern — that's the actual cost of reaching for steroids now, weighed against a kidney that can't obviously absorb a higher NSAID dose either. I'd hold the ibuprofen at its current dose rather than escalate it, add scheduled acetaminophen for breakthrough pain, and treat steroids as the fallback if he isn't better in another 48 to 72 hours — not the next scheduled step.
Agreed immediately: colchicine reduced to 0.6 mg once daily for his eGFR of 41, ibuprofen continued unchanged rather than increased, and scheduled acetaminophen added for breakthrough pain.
Not agreed, and the reason the plan carries an explicit checkpoint rather than a single expectation:
The current regimen was adequate and the steroid question never has to be answered — colchicine continues at the adjusted dose through a standard taper.
Prednisone starts at that point, accepted as a deliberate trade of higher recurrence risk for symptom control, not a default escalation.
Nephrology will recheck his renal function at 72 hours regardless of which branch this falls into, since the colchicine correction only holds if his eGFR doesn't fall further.